{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"description":"Myeloma Response Definitions - Using International Uniform Response Criteria:\n\nStringent Complete Response (sCR)requires, plus CR:\n\n* Normal free light chain ratio\n* Absence of clonal cells in bone marrow\n\nComplete Response (CR):\n\n* Absence of the original monoclonal paraprotein\n* \\<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy\n* No increase in size or number of lytic bone lesions\n* Disappearance of soft tissue plasmacytomas.","groups":[{"description":"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\\^2). Post-transplant maintenance therapy is then prescribed if appropriate.","id":"OG000","title":"Chemotherapy and Transplant Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"173 participants were not evaluable","reportingStatus":"POSTED","timeFrame":"100 Days post transplant","title":"Number of Participants Achieving a Complete Response","type":"PRIMARY","unitOfMeasure":"Participants"}